ReviewFrontiers in digital health2022
The Role of
Review in Frontiers in digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Non-Viral Nanovectors Based on Cyclodextrins for siRNA Delivery: An Update to Current Technologies.Pharmaceutics · 2026Review
- Machine learning empowered formulation design, optimization and characterization of nanoparticulate drug delivery systems: Current applications, challenges, and future perspectives.Acta pharmaceutica Sinica. B · 2026Review
- Deep Tumor Penetration Using Nanoparticle Delivery Systems: Programmed Design Strategies and Emerging Evaluation Platforms.International journal of nanomedicine · 2026Review
- Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development.MedComm · 2025Review
- Recent regulatory developments in EU Medical Device Regulation and their impact on biomaterials translation.Bioengineering & translational medicine · 2025Review
- Neuroprotective Potential of Free Radical-Scavenging Nanoparticles in Addressing Inflammation and Obesity.IET nanobiotechnology · 2025Review
- Utilizing machine learning and molecular dynamics for enhanced drug delivery in nanoparticle systems.Scientific reports · 2024Article
- Recent Progress in Terrestrial Biota Derived Antibacterial Agents for Medical Applications.Molecules (Basel, Switzerland) · 2024Review
- Nanoparticle Targeting Strategies for Lipid and Polymer-Based Gene Delivery to Immune Cells In Vivo.Small science · 2024Article
- Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Para- and Transcellular Transport Kinetics of Nanoparticles across Lymphatic Endothelial Cells.Molecular pharmaceutics · 2024Article
- Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles.Advanced functional materials · 2024Article
- Development of an ultrasound-mediated nano-sized drug-delivery system for cancer treatment: from theory to experiment.Nanomedicine (London, England) · 2024Article
- Improving ADMET Prediction Accuracy for Candidate Drugs: Factors to Consider in QSPR Modeling Approaches.Current topics in medicinal chemistry · 2024Review
- The Long Journey of Extracellular Vesicles towards Global Scientific Acclamation.Advanced pharmaceutical bulletin · 2023Review
- Perspectives on Usage of Functional Nanomaterials in Antimicrobial Therapy for Antibiotic-Resistant Bacterial Infections.ACS omega · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles (NPs) hold great potential as therapeutics, particularly in the realm of drug delivery. They are effective at functional cargo delivery and offer a great degree of amenability that can be used to offset toxic side effects or to target drugs to specific regions in the body. However, there are many challenges associated with the development of NP-based drug formulations that hamper their successful clinical translation. Arguably, the most significant barrier in the way of efficacious NP-based drug delivery systems is the tedious and time-consuming nature of NP formulation-a process that needs to account for downstream effects, such as the onset of potential toxicity or immunogenicity,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.